AU2003257055A1 - Conjugates of porphyrin compounds with chemotherapeutic agents - Google Patents

Conjugates of porphyrin compounds with chemotherapeutic agents Download PDF

Info

Publication number
AU2003257055A1
AU2003257055A1 AU2003257055A AU2003257055A AU2003257055A1 AU 2003257055 A1 AU2003257055 A1 AU 2003257055A1 AU 2003257055 A AU2003257055 A AU 2003257055A AU 2003257055 A AU2003257055 A AU 2003257055A AU 2003257055 A1 AU2003257055 A1 AU 2003257055A1
Authority
AU
Australia
Prior art keywords
porphyrin
compound
chemotherapeutic agent
group
doxorubicin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003257055A
Other languages
English (en)
Inventor
Benjamin Fryman
John A. Kink
Laurence J. Marton
Aldonia L. Valasinas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CellGate Inc
Original Assignee
CellGate Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CellGate Inc filed Critical CellGate Inc
Publication of AU2003257055A1 publication Critical patent/AU2003257055A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A61K47/546—Porphyrines; Porphyrine with an expanded ring system, e.g. texaphyrine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
AU2003257055A 2002-08-02 2003-07-30 Conjugates of porphyrin compounds with chemotherapeutic agents Abandoned AU2003257055A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40051202P 2002-08-02 2002-08-02
US60/400,512 2002-08-02
PCT/US2003/023898 WO2004012774A1 (en) 2002-08-02 2003-07-30 Conjugates of porphyrin compounds with chemotherapeutic agents

Publications (1)

Publication Number Publication Date
AU2003257055A1 true AU2003257055A1 (en) 2004-02-23

Family

ID=31495832

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003257055A Abandoned AU2003257055A1 (en) 2002-08-02 2003-07-30 Conjugates of porphyrin compounds with chemotherapeutic agents

Country Status (7)

Country Link
US (1) US20040192665A1 (enExample)
EP (1) EP1525001A1 (enExample)
JP (1) JP2005539011A (enExample)
AU (1) AU2003257055A1 (enExample)
CA (1) CA2494214A1 (enExample)
MX (1) MXPA05001222A (enExample)
WO (1) WO2004012774A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000066587A2 (en) * 1999-04-30 2000-11-09 Slil Biomedical Corporation Polyamines and their use in therapy
WO2002091989A2 (en) 2000-11-08 2002-11-21 Slil Biomedical Corporation Antiviral therapies using polyamine or polyamine analog-amino acid conjugates
EP1515973A1 (en) * 2002-06-26 2005-03-23 Cellgate Inc. Porphyrin-polyamine conjugates for cancer therapy
FR2867189A1 (fr) * 2004-03-08 2005-09-09 Ludovic Bourre Nouveaux composes medicamenteux destines au traitement des pathologies dependantes de l'activite proteine kinase
CA2573927A1 (en) 2004-07-15 2006-01-19 The University Of Sydney Porphyrin linked metronidazole against gum disease: porphyromonas gingivalis
EP2599497A3 (en) * 2008-09-08 2013-09-25 Hoffman/Barrett, L.L.C. Porphyrazine-chemotherapeutic agents conjugates
US10815276B2 (en) 2014-05-21 2020-10-27 Entrada Therapeutics, Inc. Cell penetrating peptides and methods of making and using thereof
PT3149025T (pt) 2014-05-21 2019-08-01 Entrada Therapeutics Inc Peptídeos penetrantes de células e métodos de fabrico e utilização dos mesmos
WO2016033368A1 (en) 2014-08-27 2016-03-03 Ohio State Innovation Foundation Improved peptidyl calcineurin inhibitors
CA3028122A1 (en) 2016-06-16 2017-12-21 Oncoselect Therapeutics, Llc Porphyrin compounds and compositions useful for treating cancer
EP3638248A4 (en) 2017-06-16 2021-06-30 The Regents of The University of California CONJUGATES OF PHARMACEUTICAL INGREDIENTS
US11339192B2 (en) 2017-10-04 2022-05-24 Ohio State Innovation Foundation Bicyclic peptidyl inhibitors
US11576946B2 (en) 2018-01-29 2023-02-14 Ohio State Innovation Foundation Peptidyl inhibitors of calcineurin-NFAT interaction
EP3746105A4 (en) 2018-01-29 2022-05-18 Ohio State Innovation Foundation CYCLIC PEPTIDYLIN HIBITORS OF THE CAL-PDZ-BINDING DOMAIN
WO2019165183A1 (en) 2018-02-22 2019-08-29 Entrada Therapeutics, Inc. Compositions and methods for treating mitochondrial neurogastrointestinal encephalopathy
CN108409756B (zh) * 2018-03-08 2019-12-10 莎穆(上海)生物科技有限公司 一种基于喜树碱类的异二聚体多功能前药及其制备方法和应用
CN119504769B (zh) * 2024-10-21 2025-09-30 高博药业有限公司 一种靶向her2的抗体偶联金（ⅲ）卟啉药物及其合成与肿瘤治疗应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4435087A1 (de) * 1994-09-30 1996-04-04 Deutsches Krebsforsch Konjugat zur Behandlung von Infektions-, Autoimmun- und Hauterkrankungen
US5677350A (en) * 1995-06-07 1997-10-14 Wisconsin Alumni Research Foundation Inhibition of cancer cell growth, proliferation, and metastasis using N,N'-dα,ω-diaminoalkanes
FR2764605B1 (fr) * 1997-06-17 2004-03-26 Univ Hyderabad Molecules hybrides d'un photosensibilisateur et d'un agent chimiotherapeutique, leur procede de production et leur application collaterale en chimiotherapie et therapie photodynamique
US5889061A (en) * 1997-10-15 1999-03-30 Wisconsin Alumni Research Foundation Conformationally restricted polyamines
US20020155999A1 (en) * 1998-04-30 2002-10-24 Han In Suk Method of using a porphyrin-like molecule conjugated with an anti-cancer drug for the treatment of cancer
CA2334809A1 (en) * 1998-06-05 1999-12-09 Board Of Regents, The University Of Texas System Texaphyrin conjugates and uses thereof
DE19831217A1 (de) * 1998-07-03 2000-01-05 Schering Ag Neue Porphyrinderivate, diese enthaltende pharmazeutische Mittel und ihre Verwendung in der photodynamischen Therapie und MRI-Diagnostik
US6482943B1 (en) * 1999-04-30 2002-11-19 Slil Biomedical Corporation Quinones as disease therapies
WO2001028592A1 (en) * 1999-10-15 2001-04-26 Mayo Foundation For Medical Education And Research Cobalamin conjugates useful as imaging agents and as antitumor agents
WO2002096417A1 (en) * 2001-05-31 2002-12-05 Miravant Pharmaceuticals, Inc. Substituted porphyrin and azaporphyrin derivatives and their use in photodynamic therapy, radioimaging and mri diagnosis
EP1515973A1 (en) * 2002-06-26 2005-03-23 Cellgate Inc. Porphyrin-polyamine conjugates for cancer therapy

Also Published As

Publication number Publication date
JP2005539011A (ja) 2005-12-22
CA2494214A1 (en) 2004-02-12
MXPA05001222A (es) 2005-09-12
EP1525001A1 (en) 2005-04-27
US20040192665A1 (en) 2004-09-30
WO2004012774A1 (en) 2004-02-12

Similar Documents

Publication Publication Date Title
US20040192665A1 (en) Conjugates of porphyrin compounds with chemotherapeutic agents
EP0722320B1 (en) Use of nitric oxide-releasing compounds as medicaments for hypoxic cell radiation sensitization
Renner et al. Recent progress in the syntheses and biological evaluation of boronated porphyrins for boron neutron-capture therapy
US5840759A (en) Use of nitric oxide releasing compounds to protect noncancerous cells from chemotherapeutic agents
US6207660B1 (en) Texaphyrin conjugates and uses thereof
US20020049155A1 (en) Cobalamin compounds useful as cardiovascular agents and as imaging agents
US7026347B2 (en) Porphyrin-polyamine conjugates for cancer therapy
CN1390143A (zh) 两亲型前药
US7153841B2 (en) Metal substituted non-centrosimmetrical phthalocyanine analogues, their preparation and use in photodynamic therapy and in vivo diagnostic
AU4243400A (en) Cobalamin conjugates useful as imaging agents and as antitumor agents
CN105288646A (zh) 一种光敏剂磷脂化合物、其药物组合物及应用
WO2021211975A1 (en) Photosensitizer conjugated nanoparticles for radiotherapy enhancement
US20040186087A1 (en) Siderophore conjugates of photoactive dyes for photodynamic therapy
CA2402433A1 (en) Compounds for pdt
JP5372371B2 (ja) カチオン性バクテリオクロロフィル誘導体及びその使用
EP0831806A1 (en) Multidentate metal complexes and methods of making and using thereof
WO2004063200A1 (en) Porphyrin derivatives
WO2008112251A1 (en) Cyclopropyl-containing polyamine analogs as disease therapies

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application